Establishment of replacement batches for prekallikrein activator in albumin biological reference preparation.

Pharmeuropa bio Pub Date : 2008-12-01
F Lackner, A Daas, E Terao, M-E Behr-Gross
{"title":"Establishment of replacement batches for prekallikrein activator in albumin biological reference preparation.","authors":"F Lackner,&nbsp;A Daas,&nbsp;E Terao,&nbsp;M-E Behr-Gross","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>A collaborative study was run by the European Directorate for the Quality of Medicines and HealthCare (EDQM) under the aegis of the Biological Standardisation Programme (BSP) to establish replacement batches of the current Prekallikrein activator in albumin Biological Reference Preparation (BRP) batch 1, the stocks of which were dwindling. Candidate BRP replacement batch 2 and batch 3 were assayed against the 2nd World Health Organization International Standard for Prekallikrein activator, human (2nd IS) and the Prekallikrein activator in albumin BRP batch 1. The candidate batches were manufactured from the same starting material as the current Biological Reference Preparation and the 2nd IS. They consisted of a 20 % solution of albumin lyophilised under the same conditions as the Prekallikrein activator in albumin BRP batch 1. Sixteen laboratories participated in the collaborative study and were requested to assay the candidates by their routine method, complying with the European Pharmacopoeia (Ph. Eur.) general method 2.6.15 for the determination of prekallikrein activator content. A central statistical analysis was performed at the EDQM using in-house calculations of prekallikrein activator contents provided by the participating laboratories. On the basis of the results of this study, which confirmed the assigned potency of 29 IU/vial of Prekallikrein activator in albumin BRP batch 1, the 2 candidate materials were assigned a potency of 30 IU/vial. The 2 candidates were adopted by the Ph. Eur. Commission in March 2008 as Ph. Eur. Prekallikrein activator in albumin Biological Reference Preparation batch 2 and batch 3.</p>","PeriodicalId":86996,"journal":{"name":"Pharmeuropa bio","volume":"2008 1","pages":"1-6"},"PeriodicalIF":0.0000,"publicationDate":"2008-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmeuropa bio","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

A collaborative study was run by the European Directorate for the Quality of Medicines and HealthCare (EDQM) under the aegis of the Biological Standardisation Programme (BSP) to establish replacement batches of the current Prekallikrein activator in albumin Biological Reference Preparation (BRP) batch 1, the stocks of which were dwindling. Candidate BRP replacement batch 2 and batch 3 were assayed against the 2nd World Health Organization International Standard for Prekallikrein activator, human (2nd IS) and the Prekallikrein activator in albumin BRP batch 1. The candidate batches were manufactured from the same starting material as the current Biological Reference Preparation and the 2nd IS. They consisted of a 20 % solution of albumin lyophilised under the same conditions as the Prekallikrein activator in albumin BRP batch 1. Sixteen laboratories participated in the collaborative study and were requested to assay the candidates by their routine method, complying with the European Pharmacopoeia (Ph. Eur.) general method 2.6.15 for the determination of prekallikrein activator content. A central statistical analysis was performed at the EDQM using in-house calculations of prekallikrein activator contents provided by the participating laboratories. On the basis of the results of this study, which confirmed the assigned potency of 29 IU/vial of Prekallikrein activator in albumin BRP batch 1, the 2 candidate materials were assigned a potency of 30 IU/vial. The 2 candidates were adopted by the Ph. Eur. Commission in March 2008 as Ph. Eur. Prekallikrein activator in albumin Biological Reference Preparation batch 2 and batch 3.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
白蛋白生物参比制剂中预激肽激活剂替代批次的建立。
在生物标准化计划(BSP)的支持下,欧洲药品和保健质量理事会(EDQM)开展了一项合作研究,以建立目前白蛋白生物参考制剂(BRP)第1批中Prekallikrein活化剂的替代批次,其库存正在减少。候选BRP替代品第2批和第3批对照第2世界卫生组织国际标准Prekallikrein活化剂,人(第2 IS)和白蛋白BRP第1批中的Prekallikrein活化剂进行检测。候选批由与当前生物参比制剂和第二批制剂相同的起始材料制造。它们由20%的白蛋白溶液组成,在与白蛋白BRP第1批中的prekallikin激活剂相同的条件下冻干。16个实验室参与了合作研究,按照欧洲药典(Ph. Eur.)通用方法2.6.15测定prekallikrein活化剂含量,要求按其常规方法测定候选药物。在EDQM使用参与实验室提供的预激肽激活剂含量的内部计算进行中央统计分析。在本研究结果的基础上,确定了白蛋白BRP第1批中Prekallikrein激活剂的指定效价为29 IU/瓶,2种候选材料的指定效价为30 IU/瓶。这两名候选人已被欧洲科学院博士通过。2008年3月获欧盟委员会委任为欧洲博士。白蛋白生物参比制剂第2批和第3批中的prekallikin激活剂。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Establishment of replacement batches for prekallikrein activator in albumin biological reference preparation. Evaluation of two serological methods for potency testing of whole cell pertussis vaccines. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards. Determination of Oversulphated Chondroitin Sulphate and Dermatan Sulphate in unfractionated heparin by (1)H-NMR - Collaborative study for quantification and analytical determination of LoD. Biological activity of EDQM CRS for Interferon alfa-2a and Interferon alfa-2b - assessment in two in vitro bioassays.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1